Annexin III (G-1) Antibody sc-390700 from Santa Cruz Biotechnology, Inc.

Published Figures

Register or Sign In to View Figures.

Stem Cell Reports
August 09 2022

Fig 1: Inhibition of ERK signaling blocked tooth movement induced by exosome infusion(A) Schema of the injection of ERK inhibitor U0126. Mechanical force was applied to the mice in each group for 7 days. The injections of PDLSC exosomes and U0126 were performed on the first day of tooth movement. i.v., intravenously.(B–F) The occlusal view (B and C) and three-dimensional reconstruction (D), as well as the sagittal view (E and F) by micro-CT, of the first and second molars from mice induced by PDLSC exosomes. The OTM distance was attenuated after U0126 was injected intravenously (n = 4).(G and H) TRAP staining on the compressive side of the distal root of the maxillary first molar. The number of TRAP-positive (TRAP+) osteoclast cells upregulated by exosomes was downregulated after U0126 treatment (n = 4). AB, alveolar bone; R, root; M1, first molar; M2, second molar. Blue arrows indicate the OTM distance. White and black arrows indicate the direction of the mechanical force. Scale bars, 100 µm (B, D, and E) and 200 µm (G). The results are representative of data generated from three independent experiments. Data are presented as the mean ± SD (*p < 0.05, **p < 0.01 ).(I) Schematic diagram. Compressive force promotes the biogenesis of exosomes from PDLSCs through RAB27B. Compressive force-primed PDLSC exosomes have a superior ability to promote osteoclast differentiation, which is mediated by increasing the level of exosomal ANXA3. Mechanically, exosomal ANXA3 facilitates the internalization of exosomes by macrophages to induce osteoclast differentiation by activating ERK phosphorylation, thereby accelerating the process of tooth movement. MVBs, extracellular microvesicles.
Register or Sign In to View Figures.

Stem Cell Reports
August 09 2022

Fig 2: Mechanical force enhances the enrichment of endocytic related proteins in exosomes(A) Exosomes derived from control or force-primed PDLSCs were collected and subjected to liquid chromatography-mass spectrometry (LC-MS) analysis. The identified differential proteins were used to perform heatmap analyses. The colors represent the protein concentration of each sample calculated by peak area normalization.(B) Gene ontology (GO) analysis of the upregulated proteins. BP, biological process; CC, cellular function; MF, molecular process.(C) Western blot showing the expression of ANXA3 and ANXA6 in exosomes derived from control and force-primed PDLSCs.(D) Western blot showing the expression of ANXA3 and ANXA6 in control and force-primed PDLSCs. The same amount of exosomes from each group was used for the western blot. The results are representative of data generated from three independent experiments.Data are presented as the mean ± SD (**p < 0.01). See also Figure S2 and Table S1.
Register or Sign In to View Figures.

Stem Cell Reports
August 09 2022

Fig 3: Exosomal ANXA3 activates ERK phosphorylation to promote osteoclast differentiation(A) Western blot showing the expression of ANXA3 and ANXA6 in exosomes derived from PDLSCs treated with control siRNA, ANXA3 siRNA, or ANXA6 siRNA.(B) TRAP staining images of RAW264.7 macrophages treated with PDLSC exosomes pretreated with control siRNA, ANXA3 siRNA, or ANXA6 siRNA (n = 5). Scale bars, 200 µm.(C and D) Expression of Dc-stamp and Mmp9 mRNA in RAW264.7 macrophages treated with PDLSC exosomes pretreated with control siRNA, ANXA3 siRNA, or ANXA6 siRNA, assessed by PCR.(E) Western blot showing ERK phosphorylation in RAW264.7 macrophages after being treated with PDLSC exosomes pretreated with control siRNA or ANXA3 siRNA.(F) Immunofluorescence staining showing PKH26-labeled exosomes (red) derived from PDLSCs treated with control siRNA or ANXA3 siRNA in RAW264.7 macrophages after 3 h of treatment. Cells were stained with ACTIN (green) and DAPI (blue). Scale bars, 20 µm.(G) TRAP staining images of RAW264.7 macrophages treated with ANXA3 protein for 1 day in the absence of soluble RANKL. Scale bars, 200 µm.(H and I) Expression of Dc-stamp and Mmp9 mRNA in RAW264.7 macrophages assessed by PCR after treatment with ANXA3 protein.(J) Western blot showing ERK phosphorylation in RAW264.7 macrophages after being treated with ANXA3 protein or not. Exo., exosome; siANXA3-Exo. and siANXA6-Exo., exosomes derived from PDLSCs treated with ANXA3 siRNA or ANXA6 siRNA. The same amount of exosomes from each group was used for western blots. The results are representative of data generated from three independent experiments.Data are presented as the mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.001). See also Figure S2.

Be the first to write a review!

Citations:

(1)

Figures:

Supplier Page

Supplier Page from
Santa Cruz Biotechnology, Inc. for
Annexin III (G-1) Antibody

Santa Cruz Biotechnology, Inc.'s Annexin III (G-1) Antibody is a Mouse monoclonal antibody. The Annexin III (G-1) Antibody was generated using Annexin A3, and ANXA3 as the antigen. It reacts with Homo Sapiens, and Human. This antibody has been shown to work in applications such as: EIA, Immunoassay, Precipitation, ELISA, Immunofluorescence, Immunohistochemistry - fixed, Immunoprecipitation, and Western Blot.

Stem Cell Reports

Stem Cell Reports

Stem Cell Reports

Annexin III (G-1) Antibody from Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

Citations (1)

Reviews

Annexin III (G-1) Antibody from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map